Trial Profile
Time differentiation for intravitreal treatments (IVT)between ranibizumab (Lucentis)vial and ranibizumab (Lucentis) pre-filled syringe (PFS) in real life clinical practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Diabetic retinopathy; Retinal oedema
- Focus Therapeutic Use
- Sponsors Novartis
- 12 May 2016 Status changed from active, no longer recruiting to completed.
- 05 Feb 2016 New trial record